Pursuant to Regulation 47 of SEBI (LODR), 2015, please find enclosed herewith Newspaper publication on Audited (Standalone and Consolidated) Financial Results for the Quarter and Year ended ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gennex Laboratories has filed with BSE the newspaper clippings of its audited (standalone and consolidated) financial results for the quarter and year ended March 31, 2025, as required under Regulation 47 of SEBI (LODR), 2015. The results were approved by the Board on May 30, 2025 and published in Business Standard (English) on June 2, 2025 and Saksham (Telugu local) on June 1, 2025. For FY25 on a standalone basis, the company reported total revenue from operations of about ₹5,162 lakhs and net profit after tax of approximately ₹1,645 lakhs. On a consolidated basis, FY25 PAT came in around ₹1,317.82 lakhs. Standalone basic EPS for the year was ₹0.223, with a quarterly EPS of about ₹0.065.
This is a procedural newspaper-publication filing, so no new information beyond what was already disclosed after the May 30 board meeting. The reported numbers indicate Gennex returned to a profit on a full-year basis, which is mildly positive for shareholders, but the small scale (revenue in single-digit crores) and the long listing across multiple exchanges suggest this is a very small-cap stock with limited liquidity.